Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024
For the full year, the company expects total GAAP revenue growth to be between 12% to 17%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
165.9 USD | -6.55% | -4.89% | -23.54% |
May. 10 | Raymond James Adjusts Price Target on Insulet to $213 From $218 | MT |
May. 10 | Wolfe Research Raises Price Target on Insulet to $205 From $200 | MT |
1st Jan change | Capi. | |
---|---|---|
-23.54% | 11.62B | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.84% | 40.7B | |
+24.51% | 32.25B | |
+3.43% | 26.53B | |
+15.25% | 25.02B |